Sweating Archives

Tag: Sweating

Sweating is a bodily function that helps regulate your body temperature. Also called perspiration, sweating is the release of a salt-based fluid from your sweat glands.

Changes in your body temperature, the outside temperature, or your emotional state can cause sweating. The most common areas of sweating on the body include:

armpits
face
palms of the hands
soles of the feet

Sweating in normal amounts is an essential bodily process. Not sweating enough and sweating too much can both cause problems. The absence of sweat can be dangerous because your risk of overheating increases. Excessive sweating may be more psychologically damaging than physically damaging.

06 Nov 2024

By Ronny Allan

0 Comments

Neuroendocrine Cancer – no sweat!

Living with Neuroendocrine CancerAntidepressant, Anxiety, Carcinoid syndrome, Diabetes, Flushing, Hyperhidrosis, Hyperthryroidism, Hypoglycemia, Menopause, Neuroendocrine cancer, Night sweat, Pheochromocytoma, Sleep hyperhidrosis, Sweating

I see so many questions and comments in my private group about sweating, in particular, 'night sweats' and it's prompted me to dig deeper, thus this article. When I look at a dozen decent sources of medical info, they all seem to bring up several common causes appearing on the different lists on each website I look at. I do see (so-called) carcinoid syndrome come up infrequently and perhaps the authors are lumping that in with hot flashes/flushing etc. But on authoritative NET sites (i.e. written by the NET scientific community), I do not see 'sweating' come up in the…

22 Sep 2024

By Ronny Allan

9 Comments

Don’t be underactive with your Thyroid surveillance

Living with Neuroendocrine Cancer, Patient Advocacy, Survivorship, TreatmentConstipation, Depression, Dry skin, Fatigue, Goitre, Graves’ disease, Hashimoto's disease, Heat intolerance, Hormones, Hyperthryroidism, Hypothyroidism, Lanreotide, Levothyroxine, NET syndromes, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine tumour (NET), Octreotide, Palpitation, Pituitary gland, Quality of LIfe (QoL), Radioactive iodine, Somatostatin analogues, Sweating, Thyroid stimulating hormone (TSH), Thyroiditis, Thyroxine (T4), Triiodothyronine (T3)

From other posts, you'll be aware of the thyroid lesion (approx. 17 x 19mm) which I've been tracking since 2013. The surveillance included routine thyroid blood tests, mainly TSH, T3 and 4. I was out of range in TSH (elevated) but the T4 was at the lower end of the normal range. On 20 March 2018, following an Endocrine appointment, I was put on a trial dose of 50mcg of Levothyroxine to counter the downwards trend in results indicating hypothyroidism, possibly due to the lesion. Levothyroxine is a thyroid hormone (thyroxine) replacement. One month after taking these drugs, my thyroid…

14 Dec 2016

By Ronny Allan

4 Comments

Neuroendocrine Tumours: a spotlight on Pheochromocytoma and Paraganglioma

A spotlight on NENs - Types, Awareness, Patient Advocacy, Spotlight on NENs - Types Series123I-Metaiodobenzylguanidine (mIBG), 131I-Metaiodobenzylguanidine (mIBG), 18F-FDG, 18F-FDOPA, 24-hour urinary catacholamines and metanephrines, Adrenal glands, Adrenal medulla, Adrenaline, Adrenocortical Carcinoma (ACC), Anxiety, AZEDRA, Catecholamines, EPAS1, Epinephrine, Familial NET, FH, Ga68 PET/CT, Genetics, Hormonal crisis, Hormones, Hyperadrenergic, Hypertension, Intraoperative hypertensive crisis, Iobenguane I 131, MDH2, MEN2 syndrome, MIBG scan, Multiple Endocrine Neoplasia (MEN), Nausea, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), NF1, Octreotide scan, Palpitation, Pheochromocytoma, RET, Scan, SDHA, SDHAF2(SDH5), SDHB, SDHC, SDHD, Somatostatin analogues, Surgery, Sweating, Tachycardia, The 5 E's, Vanillylmandelic acid (VMA), Von Hippel-Lindau (VHL) Syndrome

Updated 19th August 2025 I spend a lot of time talking about the most common forms of Neuroendocrine Tumours (NETs), but what about the less well-known types? As part of my commitment to all types of NETs, I'd like to shine a light on two less common tumour types known as Pheochromocytomas and Paragangliomas - with an incidence rate of approximately 8 per million per year. They are normally grouped together, and the definitions below will confirm why. If you think it's difficult to diagnose a mainstream NET, this particular sub-type is a real challenge. So, let's get definitions out…